Home/Filings/4/0001062993-24-001084
4//SEC Filing

Clayton Russell 4

Accession 0001062993-24-001084

CIK 0001374690other

Filed

Jan 18, 7:00 PM ET

Accepted

Jan 19, 4:31 PM ET

Size

7.3 KB

Accession

0001062993-24-001084

Insider Transaction Report

Form 4
Period: 2024-01-17
Clayton Russell
Chief Medical Officer
Transactions
  • Award

    Common Stock

    2024-01-17+22,50022,500 total
  • Award

    Stock Option (Right to Buy)

    2024-01-17+135,000135,000 total
    Exercise: $4.21Exp: 2034-01-17Common Stock (135,000 underlying)
Footnotes (2)
  • [F1]Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
  • [F2]The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Issuer

Larimar Therapeutics, Inc.

CIK 0001374690

Entity typeother

Related Parties

1
  • filerCIK 0001530072

Filing Metadata

Form type
4
Filed
Jan 18, 7:00 PM ET
Accepted
Jan 19, 4:31 PM ET
Size
7.3 KB